期刊
BIOCHEMICAL JOURNAL
卷 442, 期 -, 页码 465-481出版社
PORTLAND PRESS LTD
DOI: 10.1042/BJ20112092
关键词
autoimmunity; cancer; kinase inhibitor; leukaemia; lymphocyte; lymphoma; phosphoinositide 3-kinase (PI3K)
资金
- National Institutes of Health [R03-A1854621]
- University of California Industry-University Cooperative Research Program
- Infellikine
Activation of PI3K (phosphoinositide 3-kinase) is a shared response to engagement of diverse types of transmembrane receptors. Depending on the cell type and stimulus, PI3K activation can promote different fates including proliferation, survival, migration and differentiation. The diverse roles of PI3K signalling are well illustrated by studies of lymphocytes, the cells that mediate adaptive immunity. Genetic and pharmacological experiments have shown that PI3K activation regulates many steps in the development, activation and differentiation of both B- and T-cells. These findings have prompted the development of PI3K inhibitors for the treatment of autoimmunity and inflammatory diseases. PI3K activation, however, has both positive and negative roles in immune system activation. Consequently, although PI3K suppression can attenuate immune responses it can also enhance inflammation, disrupt peripheral tolerance and promote autoimmunity. An exciting discovery is that a selective inhibitor of the p110 delta catalytic isoform of P13K, CAL-101, achieves impressive clinical efficacy in certain B-cell malignancies. A model is emerging in which p110 delta inhibition disrupts signals from the lymphoid microenvironment, leading to release of leukaemia and lymphoma cells from their protective niche. These encouraging findings have given further momentum to PI3K drug development efforts in both cancer and immune diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据